Cargando…
The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD
Impairment in cognition and decline in kidney function often converge in the aging individual with chronic kidney disease (CKD). Cognitive impairment (CI) may be preventable through modification of health behaviors and risk factors that contribute to the vascular disease burden. CKD patients often h...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253558/ https://www.ncbi.nlm.nih.gov/pubmed/35800082 http://dx.doi.org/10.3389/fneur.2022.823569 |
_version_ | 1784740515696082944 |
---|---|
author | Noel, J. Ariana Hougen, Ingrid Sood, Manish M. |
author_facet | Noel, J. Ariana Hougen, Ingrid Sood, Manish M. |
author_sort | Noel, J. Ariana |
collection | PubMed |
description | Impairment in cognition and decline in kidney function often converge in the aging individual with chronic kidney disease (CKD). Cognitive impairment (CI) may be preventable through modification of health behaviors and risk factors that contribute to the vascular disease burden. CKD patients often have multiple coexisting comorbid conditions contributing to vascular risk. These comorbidities include hypertension, diabetes, cerebrovascular disease, and cardiovascular disease. Emerging evidence suggests that the management and prevention of vascular risk factors and cardiovascular diseases may indirectly contribute to the prevention of CI in CKD. Sodium glucose transport protein 2 inhibitors (SGLT2i) are emerging as the standard of care for selected individuals with CKD, type 2 diabetes (T2DM), and heart failure with rapidly expanding indications being actively investigated. In this narrative review, we examine the intriguing hypothesis that SGLT2i demonstrate potential disease modifying properties in CI among individuals with CKD. |
format | Online Article Text |
id | pubmed-9253558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92535582022-07-06 The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD Noel, J. Ariana Hougen, Ingrid Sood, Manish M. Front Neurol Neurology Impairment in cognition and decline in kidney function often converge in the aging individual with chronic kidney disease (CKD). Cognitive impairment (CI) may be preventable through modification of health behaviors and risk factors that contribute to the vascular disease burden. CKD patients often have multiple coexisting comorbid conditions contributing to vascular risk. These comorbidities include hypertension, diabetes, cerebrovascular disease, and cardiovascular disease. Emerging evidence suggests that the management and prevention of vascular risk factors and cardiovascular diseases may indirectly contribute to the prevention of CI in CKD. Sodium glucose transport protein 2 inhibitors (SGLT2i) are emerging as the standard of care for selected individuals with CKD, type 2 diabetes (T2DM), and heart failure with rapidly expanding indications being actively investigated. In this narrative review, we examine the intriguing hypothesis that SGLT2i demonstrate potential disease modifying properties in CI among individuals with CKD. Frontiers Media S.A. 2022-06-21 /pmc/articles/PMC9253558/ /pubmed/35800082 http://dx.doi.org/10.3389/fneur.2022.823569 Text en Copyright © 2022 Noel, Hougen and Sood. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Noel, J. Ariana Hougen, Ingrid Sood, Manish M. The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD |
title | The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD |
title_full | The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD |
title_fullStr | The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD |
title_full_unstemmed | The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD |
title_short | The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD |
title_sort | intersection of sglt2 inhibitors, cognitive impairment, and ckd |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253558/ https://www.ncbi.nlm.nih.gov/pubmed/35800082 http://dx.doi.org/10.3389/fneur.2022.823569 |
work_keys_str_mv | AT noeljariana theintersectionofsglt2inhibitorscognitiveimpairmentandckd AT hougeningrid theintersectionofsglt2inhibitorscognitiveimpairmentandckd AT soodmanishm theintersectionofsglt2inhibitorscognitiveimpairmentandckd AT noeljariana intersectionofsglt2inhibitorscognitiveimpairmentandckd AT hougeningrid intersectionofsglt2inhibitorscognitiveimpairmentandckd AT soodmanishm intersectionofsglt2inhibitorscognitiveimpairmentandckd |